{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T14:23:28Z","timestamp":1783607008848,"version":"3.55.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Ministry of Economy and Competitiveness | Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI22\/01088"],"award-info":[{"award-number":["PI22\/01088"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Ministry of Economy and Competitiveness | Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PMP22\/0069"],"award-info":[{"award-number":["PMP22\/0069"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Ministry of Economy and Competitiveness | Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CM24\/00155"],"award-info":[{"award-number":["CM24\/00155"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1038\/s41409-026-02871-8","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T14:53:36Z","timestamp":1778165616000},"page":"852-863","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of molecular profiling in patients with acute myeloid leukemia undergoing allogeneic transplantation in first remission: a study by the PETHEMA group"],"prefix":"10.1038","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5761-886X","authenticated-orcid":false,"given":"Rafael","family":"Colmenares","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6735-0038","authenticated-orcid":false,"given":"Eva","family":"Barrag\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2139-8540","authenticated-orcid":false,"given":"Rebeca","family":"Rodr\u00edguez-Veiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Torres-Mi\u00f1ana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"S\u00e1nchez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9622-1649","authenticated-orcid":false,"given":"Mar","family":"Tormo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2338-513X","authenticated-orcid":false,"given":"Teresa","family":"Bernal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7334-140X","authenticated-orcid":false,"given":"Pilar","family":"Mart\u00ednez-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2237-6733","authenticated-orcid":false,"given":"Eduardo","family":"Rodr\u00edguez-Arbol\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Soria-Saldise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josefina","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Colorado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0959-9449","authenticated-orcid":false,"given":"Mar\u00eda","family":"Garc\u00eda-Fortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4796-1445","authenticated-orcid":false,"given":"Cristina","family":"Bilbao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1502-3902","authenticated-orcid":false,"given":"Jos\u00e9 Luis","family":"L\u00f3pez-Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0667-1959","authenticated-orcid":false,"given":"Mar\u00eda Jos\u00e9","family":"Larr\u00e1yoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"P\u00e9rez-Santaolalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1490-0678","authenticated-orcid":false,"given":"Esperanza","family":"Lavilla-Rubira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2527-824X","authenticated-orcid":false,"given":"Lorenzo","family":"Algarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Carmen","family":"Garc\u00eda-Garay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Chill\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Torres-Ochando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Couto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raimundo","family":"Garc\u00eda-Boyero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8733-3171","authenticated-orcid":false,"given":"\u00c1gata","family":"Almela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edctor","family":"Noriega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Callejas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7578-2030","authenticated-orcid":false,"given":"Manuel","family":"Barrios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soledad","family":"Casado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5022-2045","authenticated-orcid":false,"given":"Amaia","family":"Balerdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Cabello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3696-0287","authenticated-orcid":false,"given":"Jorge","family":"Labrador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Carmen","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3356-9290","authenticated-orcid":false,"given":"Mar\u00eda Luz","family":"Amigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"P\u00e9rez-Encinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Garc\u00eda-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lissette","family":"Costilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Bergua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9570-5542","authenticated-orcid":false,"given":"Gonzalo","family":"Carre\u00f1o-Tarragona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7908-0063","authenticated-orcid":false,"given":"Joaqu\u00edn","family":"Mart\u00ednez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2699-8353","authenticated-orcid":false,"given":"Rosa","family":"Ayala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3275-5593","authenticated-orcid":false,"given":"Pau","family":"Montesinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the PETHEMA Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"key":"2871_CR1","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","volume":"368","author":"The Cancer Genome Atlas Research Network","year":"2013","unstructured":"The Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368:2059\u201374.","journal-title":"N Engl J Med"},{"key":"2871_CR2","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H D\u00f6hner","year":"2015","unstructured":"D\u00f6hner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373:1136\u201352.","journal-title":"N Engl J Med"},{"key":"2871_CR3","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209\u201321.","journal-title":"N Engl J Med"},{"key":"2871_CR4","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424\u201347.","journal-title":"Blood"},{"key":"2871_CR5","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"key":"2871_CR6","doi-asserted-by":"publisher","first-page":"4167","DOI":"10.1200\/JCO.2015.62.7273","volume":"33","author":"SM Devine","year":"2015","unstructured":"Devine SM, Owzar K, Blum W, Mulkey F, Stone RM, Hsu JW, et al. Phase II Study of allogeneic transplantation for older patients with acute myeloid leukemia in first complete remission using a reduced-intensity conditioning regimen: results from Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)\/blood and marrow transplant clinical trial network 0502. JCO. 2015;33:4167\u201375.","journal-title":"JCO"},{"key":"2871_CR7","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1182\/blood.2019003662","volume":"135","author":"SO Ciurea","year":"2020","unstructured":"Ciurea SO, Kongtim P, Varma A, Rondon G, Chen J, Srour S, et al. Is there an optimal conditioning regimen for older patients with AML receiving allogeneic hematopoietic cell transplantation? Blood. 2020;135:449\u201352.","journal-title":"Blood"},{"key":"2871_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01223-x","volume":"15","author":"C Jim\u00e9nez-Vicente","year":"2025","unstructured":"Jim\u00e9nez-Vicente C, Esteve J, Baile-Gonz\u00e1lez M, P\u00e9rez-L\u00f3pez E, Mart\u00edn Calvo C, Aparicio C, et al. Allo-HCT refined ELN 2022 risk classification: validation of the Adverse-Plus risk group in AML patients undergoing allogeneic hematopoietic cell transplantation within the Spanish Group for Hematopoietic Cell Transplantation (GETH-TC). Blood Cancer J. 2025;15:42.","journal-title":"Blood Cancer J"},{"key":"2871_CR9","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.3324\/haematol.2020.263806","volume":"106","author":"C Sargas","year":"2020","unstructured":"Sargas C, Ayala R, Chill\u00f3n MC, Larr\u00e1yoz MJ, Carrillo-Cruz E, Bilbao C, et al. Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project. haematol. 2020;106:3079\u201389.","journal-title":"haematol"},{"key":"2871_CR10","doi-asserted-by":"publisher","first-page":"3436","DOI":"10.1002\/cncr.35431","volume":"130","author":"J Labrador","year":"2024","unstructured":"Labrador J, Mart\u00ednez-Cuadr\u00f3n D, Boluda B, Serrano J, Gil C, P\u00e9rez-Sim\u00f3n JA, et al. Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real-life data from the PETHEMA Registry. Cancer. 2024;130:3436\u201351.","journal-title":"Cancer"},{"key":"2871_CR11","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15:1628\u201333.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2871_CR12","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.jmoldx.2018.09.009","volume":"21","author":"CM Alonso","year":"2019","unstructured":"Alonso CM, Llop M, Sargas C, Pedrola L, Panadero J, Herv\u00e1s D, et al. Clinical utility of a next-generation sequencing panel for acute myeloid leukemia diagnostics. J Mol Diagn. 2019;21:228\u201340.","journal-title":"J Mol Diagn"},{"key":"2871_CR13","doi-asserted-by":"publisher","first-page":"438","DOI":"10.3390\/cancers15020438","volume":"15","author":"C Sargas","year":"2023","unstructured":"Sargas C, Ayala R, Larr\u00e1yoz MJ, Chill\u00f3n MC, Carrillo-Cruz E, Bilbao-Sieyro C, et al. Molecular landscape and validation of new genomic classification in 2668 adult AML patients: Real-life data from the PETHEMA registry. Cancers. 2023;15:438.","journal-title":"Cancers"},{"key":"2871_CR14","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","volume":"33","author":"N Daver","year":"2019","unstructured":"Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019;33:299\u2013312.","journal-title":"Leukemia"},{"key":"2871_CR15","doi-asserted-by":"publisher","first-page":"3636","DOI":"10.1200\/JCO.2010.28.3762","volume":"28","author":"P Paschka","year":"2010","unstructured":"Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Kr\u00f6nke J, Bullinger L, et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol. 2010;28:3636\u201343.","journal-title":"J Clin Oncol"},{"key":"2871_CR16","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1182\/blood-2009-11-250878","volume":"116","author":"S Abbas","year":"2010","unstructured":"Abbas S, Lugthart S, Kavelaars FG, Schelen A, Koenders JE, Zeilemaker A, et al. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Blood. 2010;116:2122\u20136.","journal-title":"Blood"},{"key":"2871_CR17","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1111\/ejh.12271","volume":"92","author":"S Yamaguchi","year":"2014","unstructured":"Yamaguchi S, Iwanaga E, Tokunaga K, Nanri T, Shimomura T, Suzushima H, et al. IDH1 and IDH2 mutations confer an adverse effect in patients with acute myeloid leukemia lacking the NPM1 mutation. Eur J Haematol. 2014;92:471\u20137.","journal-title":"Eur J Haematol"},{"key":"2871_CR18","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1182\/bloodadvances.2021005789","volume":"7","author":"M Bill","year":"2023","unstructured":"Bill M, Jentzsch M, Bischof L, Kohlschmidt J, Grimm J, Schmalbrock LK, et al. Impact of IDH1 and IDH2 mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation. Blood Adv. 2023;7:436\u201344.","journal-title":"Blood Adv"},{"key":"2871_CR19","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1182\/blood.2024024310","volume":"144","author":"J Othman","year":"2024","unstructured":"Othman J, Potter N, Ivey A, Tazi Y, Papaemmanuil E, Jovanovic J, et al. Molecular, clinical, and therapeutic determinants of outcome in NPM1 -mutated AML. Blood. 2024;144:714\u201328.","journal-title":"Blood"},{"key":"2871_CR20","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1080\/16078454.2021.1880753","volume":"26","author":"WS Zheng","year":"2021","unstructured":"Zheng WS, Hu YL, Guan LX, Peng B, Wang SY. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations. Hematology. 2021;26:179\u201385.","journal-title":"Hematology"},{"key":"2871_CR21","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/ejh.13216","volume":"102","author":"I Pasic","year":"2019","unstructured":"Pasic I, Da\u2019na W, Lam W, Law A, Lipton JH, Viswabandya A, et al. Influence of FLT3-ITD and NPM1 status on allogeneic hematopoietic cell transplant outcomes in patients with cytogenetically normal AML. Eur J Haematol. 2019;102:368\u201374.","journal-title":"Eur J Haematol"},{"key":"2871_CR22","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1182\/blood-2013-12-544957","volume":"123","author":"JM Middeke","year":"2014","unstructured":"Middeke JM, Fang M, Cornelissen JJ, Mohr B, Appelbaum FR, Stadler M, et al. Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. Blood. 2014;123:2960\u20137.","journal-title":"Blood"},{"key":"2871_CR23","doi-asserted-by":"publisher","first-page":"5681","DOI":"10.1182\/bloodadvances.2020003120","volume":"4","author":"NJ Short","year":"2020","unstructured":"Short NJ, Montalban-Bravo G, Hwang H, Ning J, Franquiz MJ, Kanagal-Shamanna R, et al. Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. Blood Adv. 2020;4:5681\u20139.","journal-title":"Blood Adv"},{"key":"2871_CR24","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41375-023-01847-7","volume":"37","author":"T Badar","year":"2023","unstructured":"Badar T, Atallah E, Shallis R, Saliba AN, Patel A, Bewersdorf JP, et al. Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Leukemia. 2023;37:799\u2013806.","journal-title":"Leukemia"},{"key":"2871_CR25","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.3324\/haematol.2018.189043","volume":"103","author":"FM Tien","year":"2018","unstructured":"Tien FM, Hou HA, Tang JL, Kuo YY, Chen CY, Tsai CH, et al. Concomitant WT1 mutations predict poor prognosis in acute myeloid leukemia patients with double mutant CEBPA. Haematologica. 2018;103:e510\u20133.","journal-title":"Haematologica"},{"key":"2871_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.632094","volume":"11","author":"Y Wang","year":"2021","unstructured":"Wang Y, Weng WJ, Zhou DH, Fang JP, Mishra S, Chai L, et al. Wilms tumor 1 mutations are independent poor prognostic factors in pediatric acute myeloid leukemia. Front Oncol. 2021;11:632094.","journal-title":"Front Oncol"},{"key":"2871_CR27","first-page":"22","volume":"40","author":"S Ma","year":"2025","unstructured":"Ma S, Tang L, Tang H, Wu C, Pu X, Yang J, et al. WT1 and DNMT3A mutations in prognostic significance of acute myeloid leukemia: a meta-analysis. Cancer Biother Radiopharm. 2025;40:22\u201330.","journal-title":"Cancer Biother Radiopharm"},{"key":"2871_CR28","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1002\/ajh.24306","volume":"91","author":"BK Hamilton","year":"2016","unstructured":"Hamilton BK, Visconte V, Jia X, Tabarroki A, Makishima H, Hasrouni E, et al. Impact of allogeneic hematopoietic cell transplant in patients with myeloid neoplasms carrying spliceosomal mutations. Am J Hematol. 2016;91:406\u20139.","journal-title":"Am J Hematol"},{"key":"2871_CR29","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1038\/s41409-022-01817-0","volume":"57","author":"GY Song","year":"2022","unstructured":"Song GY, Kim T, Ahn SY, Jung SH, Kim M, Yang DH, et al. Allogeneic hematopoietic cell transplantation can overcome the adverse prognosis indicated by secondary-type mutations in de novo acute myeloid leukemia. Bone Marrow Transpl. 2022;57:1810\u20139.","journal-title":"Bone Marrow Transpl"},{"key":"2871_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00764-9","volume":"12","author":"M Jentzsch","year":"2022","unstructured":"Jentzsch M, Bischof L, Ussmann J, Backhaus D, Brauer D, Metzeler KH, et al. Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantation. Blood Cancer J. 2022;12:170.","journal-title":"Blood Cancer J"},{"key":"2871_CR31","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1038\/s41375-023-01884-2","volume":"37","author":"C Rausch","year":"2023","unstructured":"Rausch C, Rothenberg-Thurley M, Dufour A, Schneider S, Gittinger H, Sauerland C, et al. Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia. Leukemia. 2023;37:1234\u201344.","journal-title":"Leukemia"},{"key":"2871_CR32","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1002\/ajh.26892","volume":"98","author":"M Lo","year":"2023","unstructured":"Lo M, Tsai XC, Lin C, Tien F, Kuo Y, Lee W, et al. Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy-treated aged 18 to 65 years patients with de novo acute myeloid leukemia. Am J Hematol. 2023;98:760\u20139.","journal-title":"Am J Hematol"},{"key":"2871_CR33","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/bmt.2011.110","volume":"47","author":"A Gratwohl","year":"2012","unstructured":"Gratwohl A. The EBMT risk score. Bone Marrow Transpl. 2012;47:749\u201356.","journal-title":"Bone Marrow Transpl"},{"key":"2871_CR34","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912\u20139.","journal-title":"Blood"},{"key":"2871_CR35","doi-asserted-by":"publisher","first-page":"3249","DOI":"10.1200\/JCO.2013.53.8157","volume":"32","author":"ML Sorror","year":"2014","unstructured":"Sorror ML, Storb RF, Sandmaier BM, Maziarz RT, Pulsipher MA, Maris MB, et al. Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. J Clin Oncol. 2014;32:3249\u201356.","journal-title":"J Clin Oncol"},{"key":"2871_CR36","doi-asserted-by":"crossref","unstructured":"Wang QY, Han YF, Li YH, Wang QY, Zhu JY, Dong YJ, et al. A novel prognostic scoring system for AML patients undergoing allogeneic hematopoietic stem cell transplantation with real-world validation. J Adv Res. 2024;73:671\u20139.","DOI":"10.1016\/j.jare.2024.09.014"},{"key":"2871_CR37","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41409-025-02527-z","volume":"60","author":"J Sanz","year":"2025","unstructured":"Sanz J, Labopin M, Versluis J, Blaise D, Lazzari L, Montoro J, et al. Cytogenetic and molecular risk-driven conditioning intensity in acute myeloid leukemia patients undergoing stem cell transplantation with post-transplant cyclophosphamide: a study from the acute leukemia working party of the EBMT. Bone Marrow Transpl. 2025;60:529\u201334.","journal-title":"Bone Marrow Transpl"},{"key":"2871_CR38","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.bbmt.2014.11.007","volume":"21","author":"N Bejanyan","year":"2015","unstructured":"Bejanyan N, Weisdorf DJ, Logan BR, Wang HL, Devine SM, De Lima M, et al. Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study. Biol Blood Marrow Transplant. 2015;21:454\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2871_CR39","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1200\/JCO.19.03345","volume":"38","author":"A Burchert","year":"2020","unstructured":"Burchert A, Bug G, Fritz LV, Finke J, Stelljes M, R\u00f6llig C, et al. Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3 \u2013internal tandem duplication mutation (SORMAIN). J Clin Oncol. 2020;38:2993\u20133002.","journal-title":"J Clin Oncol"},{"key":"2871_CR40","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1200\/JCO.23.02474","volume":"42","author":"MJ Levis","year":"2024","unstructured":"Levis MJ, Hamadani M, Logan B, Jones RJ, Singh AK, Litzow M, et al. Gilteritinib as Post-transplant maintenance for AML with internal tandem duplication mutation of FLT3. J Clin Oncol. 2024;42:1766\u201375.","journal-title":"J Clin Oncol"},{"key":"2871_CR41","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1158\/1078-0432.CCR-23-0182","volume":"29","author":"AT Fathi","year":"2023","unstructured":"Fathi AT, Kim HT, Soiffer RJ, Levis MJ, Li S, Kim AS, et al. Multicenter phase I trial of ivosidenib as maintenance treatment following allogeneic hematopoietic cell transplantation for IDH1 -mutated acute myeloid leukemia. Clin Cancer Res. 2023;29:2034\u201342.","journal-title":"Clin Cancer Res"},{"key":"2871_CR42","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1182\/blood.2024024010","volume":"145","author":"GJ Roboz","year":"2025","unstructured":"Roboz GJ, Canaani J. How I use maintenance therapy in acute myeloid leukemia. Blood. 2025;145:1273\u201381.","journal-title":"Blood"},{"key":"2871_CR43","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1200\/JCO.2007.11.1641","volume":"26","author":"D Valc\u00e1rcel","year":"2008","unstructured":"Valc\u00e1rcel D, Martino R, Caballero D, Mart\u00edn J, Ferra C, Nieto JB, et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. J Clin Oncol. 2008;26:577\u201384.","journal-title":"J Clin Oncol"},{"key":"2871_CR44","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1038\/leu.2012.135","volume":"26","author":"F Baron","year":"2012","unstructured":"Baron F, Labopin M, Niederwieser D, Vigouroux S, Cornelissen JJ, Malm C, et al. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation. Leukemia. 2012;26:2462\u20138.","journal-title":"Leukemia"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02871-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02871-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02871-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T14:03:54Z","timestamp":1783605834000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02871-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":44,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["2871"],"URL":"https:\/\/doi.org\/10.1038\/s41409-026-02871-8","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"assertion":[{"value":"19 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}